p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer

European Journal of Cancer

Volumn 36, Issue 8, 2000, Pages 1008-1015

  Bouzourene, H ^a   Gervaz, P ^b   Cerottini, J P ^b   Benhattar, J ^a   Chaubert, P ^a   Saraga, E ^a   Pampallona, S ^c   Bosman, F T ^a   Givel, J C ^b  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ForMed   (Switzerland)

Author keywords

Colorectal carcinoma; Dukes' B; p53 expression; Survival; TP53 mutation

Indexed keywords

PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CODON; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034026701     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00036-8     Document Type: Article

References (42)

1. Deans G.T., Parks T.G., Rowlands B.J., Spence R.A.J. Prognostic factors in colorectal cancer. Br. J. Surg. 79:1992;608-613.
2. Fielding L.P., Philips R.K.S., Fry J.S., Hittinger R. Prediction of outcome after curative resection for large bowel cancer. Lancet. 2:1986;904-907.
3. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
4. Dix B.R., Robbins P., Soong R., Jenner D., House A.K., Iacopetta B.J. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer. 59:1994;747-751.
5. Soong R., Robbins P.D., Dix B.R.et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum. Pathol. 27:1995;1050-1055.
6. Bennett M.A., Kay E.W., Mulcahy H.et al. Ras and p53 in the prediction of survival in Dukes's stage B colorectal carcinoma. J. Clin. Pathol. 48:1995;M310-M315.
7. Mulder J.W., Baas I.O., Polak M.M., Goodman S.N., Offerhaus G.H. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br. J. Cancer. 71:1995;1257-1262.
8. Leahy D.T., Salman R., Mulcahy H., Sheahan K., O'Donoghue D.P., Parfray N.A. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J. Pathol. 180:1996;364-370.
9. Ahnen D.J., Feigl P., Quan G.et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. a Southwest Oncology Group study Cancer Res. 58:1998;1149-1158.
10. Andreyev H.J.N., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer. The multicenter "RASCAL'' study. J. Natl. Cancer Inst. 90:1998;675-684.
11. Dukes C.E. Histologic grading of rectal carcinoma. Pro. R. Soc. Med. 30:1937;371-376.
12. World Health Organization International Histological Classification of Tumors. No 15. Histological Typing of Intestinal Tumors. 1976;WHO, Geneva.
13. Losi L., Benhattar J., Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur. J. Cancer. 28A:1992;1115-1120.
14. Chaubert P., Bautista D., Benhattar J. An improved method for rapid screening of DNA mutations by non-radioactive single-strand conformation polymorphism procedure. Biotechniques. 15:1993;586.
15. Hurlimann J., Chaubert P., Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas. correlation between immunohistochemical and molecular biology techniques Mod. Pathol. 7:1994;423-428.
16. Stata. Computing Resource Centre Reference Manual, 1991.
17. Saraga E., Batista D., Dorta G.et al. Genetic heterogeneity in sporadic colorectal adenomas. J. Pathol. 181:1997;281-286.
18. Shaw P., Tardy S., Benito E., Ogrador A., Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene. 6:1991;2121-2128.
19. Laurent-Puig P., Olschwang S., Delattre O., Remuikos Y. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 102:1992;1136-1141.
20. Bell S.M., Scot N., Cross D.et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 104:1993;57-64.
21. Morrin M., Kelly M., Barrett N., Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut. 35:1994;1627-1631.
22. Tanaka M., Omura K., Watanabe Y., Oda Y., Nakanishi I. Prognostic factors of colorectal cancer. K-ras mutation, overexpression of the p53 protein and cell proliferative activity J. Surg. Oncology. 57:1994;57-64.
23. Pricolo V.E., Finkelstein S.D., Hansen K., Cole B.F., Bland K. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch. Surg. 132:1997;371-375.
24. Fung C., Bragg T., Newland R.et al. K-ras mutation and loss of heterozygosity of chromosome 17p and survival in colorectal cancer. Aust. N.Z. J. Surg. 67:1997;239-244.
25. Pauly M., Schmitz M., Kayse I.et al. Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. Eur. J. Cancer. 33:1997;2265-2272.
26. Vogelstein B., Fearon E.R., Hamilton S.R.et al. Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319:1988;525-532.
27. Benhattar J., Losi L., Chaubert P., Givel J.C., Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 104:1993;1044-1048.
28. Michelassi F., Grad G., Erroi F., Roncella M., Romagnoli J., Handcock M. Relationship between ras oncogene expression and pathological features of colonic carcinoma. Hepatogastroenterology. 37:1990;513-516.
29. Sun X.F., Hatschek T., Wingren S.et al. Ras p21 expression in relation to histopathological variables and prognosis in colorectal adenocarcinoma. Acta. Oncol. 30:1991;933-939.
30. Halter S., Webb L., Rose J. Lack of ras mutations and prediction of long-term survival in carcinoma of the colon. Mod. Pathol. 5:1992;131-134.
31. McLeod H.L., Murray G.I. Tumour markers of prognosis in colorectal cancer. Br. J. Cancer. 79:1999;191-203.
32. Bosari S., Viale G., Bosse P.et al. Cytoplasmic accumulation of p53 protein. an independent prognostic indicator in colorectal adenocarcinomas J. Natl. Cancer Inst. 86:1994;681-687.
33. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc700 p53 complex with an altered half-life. Mol. Cell. Biol. 8:1988;531-539.
34. Cripps K.J., Purdie C.A., Carder P.J.et al. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene. 9:1994;2739-2743.
35. Caldes T., Iniesta P., Vega F.J.et al. Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer. Oncology. 55:1998;249-257.
36. El-Mahdani N., Vaillant J.C., Guiguet M.et al. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br. J. Cancer. 75:1997;528-536.
37. Wynford-Thomas D. p53 in tumour pathology. can we trust immunocytochemistry? J. Pathol. 166:1992;329-330.
38. Kussie P.H., Gorina S., Marechal V.et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;948-953.
39. Giaretti W., Monaco R., Pujic N., Rapallo A., Nigro S., Geido E. Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas. Am. J. Pathol. 149:1996;237-245.
40. Shibata D., Schaeffer J., Li Z.H., Capella G., Perucho M. Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. J. Natl. Cancer Inst. 85:1993;1058-1063.
41. Andreyev H.J.N., Tilsed J.V.T., Cunningham S.A., Norman A.R., Schneider H.J., Clarke P.A. K-ras mutations in patients with early colorectal cancers. Gut. 41:1997;323-329.
42. Kojima M., Konishi F., Tsukamoto T., Yamashita K., Kanazawa K. Ki-ras point mutation in different types of colorectal carcinomas in early stages. Dis. Colon. Rectum. 40:1997;161-167.